Aprea Therapeutics, Inc. ( (APRE) ) has released its Q2 earnings. Here is a breakdown of the information Aprea Therapeutics, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells.
In its latest earnings report, Aprea Therapeutics highlighted promising clinical advancements and financial results for the second quarter of 2025. The company reported early evidence of disease control in its ongoing trials and maintained a cash position of $16.5 million as of June 30, 2025.
Key financial metrics revealed a decrease in operating loss to $3.4 million from the previous year’s $3.8 million, alongside a reduction in research and development expenses to $1.9 million. The company also reported a net loss of $3.2 million for the quarter, reflecting a slight improvement over the previous year. Clinically, Aprea’s trials for its WEE1 inhibitor, APR-1051, and ATR inhibitor, ATRN-119, showed encouraging signs of efficacy and tolerability, with several patients achieving stable disease and tumor shrinkage.
Looking ahead, Aprea Therapeutics remains optimistic about its clinical programs, with plans to continue dose escalation and explore combination therapies to address unmet medical needs. The company anticipates further safety and efficacy data releases in the latter half of 2025, which could inform future clinical strategies.